• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
In search of the optimal proteosome inhibitor. How, when and for whom?寻找最佳蛋白酶体抑制剂。如何、何时以及针对何人？
Haematologica. 2021 Oct 1;106(10):2539-2541. doi: 10.3324/haematol.2021.278838.
2
Use of proteasome inhibitors.
Curr Protoc Immunol. 2015 Apr 1;109:9.10.1-9.10.8. doi: 10.1002/0471142735.im0910s109.
3
Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.鉴定一种有效的天然三萜类化合物，其为蛋白酶体糜蛋白酶样活性和NF-κB的抑制剂，在体外和体内均具有抗骨髓瘤活性。
Blood. 2009 Apr 23;113(17):4027-37. doi: 10.1182/blood-2008-09-179796. Epub 2008 Dec 18.
4
Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades.蛋白酶体抑制剂通过破坏p62、TRAF6、CYLD和IkappaBalpha信号级联反应，损害破骨细胞样细胞中RANKL诱导的NF-κB活性。
J Cell Physiol. 2009 Aug;220(2):450-9. doi: 10.1002/jcp.21787.
5
Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.
Clin Transpl. 2010:421-8.
6
[Expression, purification of proteasome subunit PSMB1 and application in screening of possible proteasome inhibitors].蛋白酶体亚基PSMB1的表达、纯化及其在潜在蛋白酶体抑制剂筛选中的应用
Sheng Wu Gong Cheng Xue Bao. 2012 Feb;28(2):233-42.
7
Search for Inhibitors of the Ubiquitin-Proteasome System from Natural Sources for Cancer Therapy.从天然来源寻找泛素-蛋白酶体系统抑制剂用于癌症治疗
Chem Pharm Bull (Tokyo). 2016;64(2):112-8. doi: 10.1248/cpb.c15-00768.
8
High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design.蛋白酶体抑制剂作用的高分辨率快照修正了抑制模式并启发了下一代抑制剂的设计。
Chembiochem. 2016 Nov 17;17(22):2115-2117. doi: 10.1002/cbic.201600488. Epub 2016 Oct 11.
9
GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.GSI-I（Z-LLNle-CHO）通过抑制γ-分泌酶和蛋白酶体来诱导前体 B 急性淋巴细胞白血病细胞死亡。
Leukemia. 2011 Jul;25(7):1135-46. doi: 10.1038/leu.2011.50. Epub 2011 Apr 15.
10
Recent advances in proteasome inhibitor-based cancer therapies.基于蛋白酶体抑制剂的癌症治疗的最新进展。
Curr Cancer Drug Targets. 2014;14(6):505. doi: 10.2174/1568009614666140805163018.

本文引用的文献

1
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK).卡非佐米或硼替佐米联合环磷酰胺和地塞米松治疗一线治疗后多发性骨髓瘤患者：来自多中心、Ⅱ期、随机、对照试验（MUK）的结果。
Haematologica. 2021 Oct 1;106(10):2694-2706. doi: 10.3324/haematol.2021.278399.
2
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.卡非佐米、来那度胺、地塞米松和环磷酰胺（KRdc）作为适合移植的新诊断多发性骨髓瘤患者的诱导治疗（Myeloma XI+）：一项开放标签随机对照试验的中期分析。
PLoS Med. 2021 Jan 11;18(1):e1003454. doi: 10.1371/journal.pmed.1003454. eCollection 2021 Jan.
3
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.卡非佐米或硼替佐米联合来那度胺和地塞米松治疗无即刻自体干细胞移植意向的新诊断多发性骨髓瘤患者（ENDURANCE）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.
4
Once-weekly (70 mg/m ) vs twice-weekly (56 mg/m ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials.复发或难治性多发性骨髓瘤患者中卡非佐米每周一次（70mg/m²）与每周两次（56mg/m²）给药的比较：ENDEAVOR、A.R.R.O.W.和CHAMPION-1试验的事后分析
Cancer Med. 2020 May;9(9):2989-2996. doi: 10.1002/cam4.2945. Epub 2020 Feb 28.
5
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies.卡非佐米、环磷酰胺和地塞米松用于不适合移植的新诊断高危骨髓瘤患者：两项研究的 pooled 分析。
Haematologica. 2021 Apr 1;106(4):1079-1085. doi: 10.3324/haematol.2019.243428.
6
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.卡非佐米或硼替佐米联合马法兰-泼尼松用于不适合移植的新诊断多发性骨髓瘤患者。
Blood. 2019 May 2;133(18):1953-1963. doi: 10.1182/blood-2018-09-874396. Epub 2019 Feb 28.
7
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.新诊断的不适合移植骨髓瘤患者中每周使用卡非佐米、环磷酰胺和地塞米松的 1/2 期研究。
Leukemia. 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16.
8
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.硼替佐米、环磷酰胺和地塞米松作为多发性骨髓瘤诱导疗法的II期研究：DSMM XI试验
Br J Haematol. 2017 Nov;179(4):586-597. doi: 10.1111/bjh.14920. Epub 2017 Sep 29.
9
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.卡非佐米或硼替佐米治疗复发或难治性多发性骨髓瘤（ENDEAVOR）：一项开放标签、随机、3 期临床试验的中期总生存分析。
Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23.
10
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.硼替佐米与地塞米松联用环磷酰胺或来那度胺治疗新诊断多发性骨髓瘤的疗效、医疗资源利用及成本
Leukemia. 2016 Apr;30(4):995-8. doi: 10.1038/leu.2015.225. Epub 2015 Aug 14.

In search of the optimal proteosome inhibitor. How, when and for whom?

作者信息

Engelhardt Monika, Bringhen Sara, Moreau Philippe, Wäsch Ralph, Waldschmidt Johannes

机构信息

University of Freiburg, Hematology and Oncology, Faculty of Freiburg, Hugstetterstr. 53, 79106 Freiburg.

Myeloma Unit, Division of Hematology, University of Turino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino.

出版信息

Haematologica. 2021 Oct 1;106(10):2539-2541. doi: 10.3324/haematol.2021.278838.

DOI:10.3324/haematol.2021.278838
PMID:33910336
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8485685/
Abstract
摘要